Brief: US FDA Approves Leqembi® IQKLIK™ (lecanemab-irmb) Subcutaneous Injection For Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
29/08/2025 23:22
Aug 29 (Reuters) - BioArctic AB BIOAb.ST: US FDA APPROVES LEQEMBI® IQKLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION FOR MAINTENANCE DOSING FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE Source text: ID:nPreZJfx0a Further company coverage: [BIOAb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln